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Abstract  
The Chilean healthcare system is composed of public and private sectors, with most of the higher-income population being covered 
privately. Primary healthcare in the public system is provided in more than 2,500 public primary care centers of different sizes with 
assigned populations within territories. Private insurance companies have their own healthcare networks or buy services from 
individual health providers. Patients from the public system receive most medications free of charge in primary care pharmacies 
embedded in each care center. Private patients must purchase their medicines from community pharmacies. Some government 
policies subsidize part of the cost of medications, but original medicines remain as the most expensive of Latin America. Three chain 
pharmacies have more than 90% of the market share, and these pharmacies have negative public perception because of price collusion 
court sentences. A non-profit, municipal pharmacy model was developed but has limited implementation. Most privately owned 
independent and chain community pharmacies do not provide pharmaceutical services as there is no remuneration or cover by 
insurers. The limited number of publicly owned Municipal pharmacies could implement pharmaceutical services in community settings 
as they are non-profit establishments and have full-time pharmacists but are not resourced for these services. A limited number of 
pharmaceutical services are almost exclusively provided in public primary care, including medication reviews, pharmaceutical 
education, home visits and pharmacovigilance services, but several barriers to their implementation remain. A risk-based 
multimorbidity care model was implemented in 2020 for public primary care with additional employment of part-time pharmacists to 
provide services. We believe that this model will help pharmacists to optimize their time by prioritizing the much-needed clinical tasks. 
We propose within this multimorbidity care model that the more time-consuming services are provided to higher risk patients. 
Pharmacy prescribing i.e. amending or approving changes in medications in primary care for chronic conditions could also be useful for 
the health system, but pharmacists would require additional training. The landscape for pharmaceutical services for primary care in 
Chile is promising, but the integration with community pharmacies will not be possible until they are funded by public and private 
insurance, and the public perception of these establishments is improved. 
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CHILEAN HEALTHCARE SYSTEM AND PRIMARY 
CARE 
Chile is a country of 17.5 million people, composed of 16 
regional governments, and 349 local governments called 
municipalities.1 Chile’s gross domestic product (GDP) per 
capita for 2019 was USD 14,896.2 Chile is a member of the 
Organization for Economic Co-operation and Development 
(OECD) and is classified as a high-income country but has a 
very high inequality index (Gini coefficient of 0.46).3 Twenty 
percent of the country’s population earns 51.3% of the 
GDP.2 In 2019 Chile spent USD 2,159 per capita or 9.1% of 
its GDP in healthcare, which is about half the OECD average 
of USD 4,224 per capita. Of this spending, 34% were out-of-
pocket payments made by patients, the third largest of the 
OECD.3  
The Chilean healthcare system is a two-tier system with a 
public and private sector. Chileans are mandated to pay 7% 
of their salaries for health insurance (except for retired 
older adults who continue working) with an option to 
choose either public or private health cover.4 Private health 
companies [Instituciones de Salud Previsional] (ISAPRESs) 
cover 19.6% of the population but receive about 54% of 
health funding.5 These private companies tend to cover 
younger men with higher income driven by unregulated 
premiums that discriminate by sex and age.5 Eighty percent 
of the citizens are covered by the public national health 
fund [Fondo Nacional de Salud] (FONASA) including high-
risk groups that use more resources posing an increased 
burden.5-6 In 2006, the government implemented the 
Explicit Health Guarantees System [Garantías Explícitas en 
Salud] (GES). GES is a group of enforceable benefits for 
FONASA and ISAPREs beneficiaries. Their main objective is 
to ensure timely access to healthcare while protecting the 
extent of the population out of pocket expenditure. 
Currently, GES covers 85 conditions.6-7 Nonetheless, 
conditions that are not covered by GES have long waiting 
times, and usually will require high out-of-pocket 
payments. An additional program was introduced in 2015 
to avoid catastrophic health expenses by covering high-cost 
rare diseases such as multiple sclerosis and Huntington’s 
disease.8 
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Most patients insured by ISAPREs use private providers for 
primary, secondary and hospital care. Their focus is on 
treatment of diseases, with little incentive to perform 
health prevention activities.5 In contrast, the public system 
has its own infrastructure and is mandated by the Ministry 
of Health. The public health sector is coordinated by the 
sub secretariat of Assistance Networks of the Ministry of 
Health, regulating and supervising healthcare services.9 This 
sub secretariat coordinates the National System of Health 
Services, or 29 autonomous administrators that oversee 
their local network of primary and secondary care, as well 
as emergency and hospital treatment.9 From 2004, the 
main objective of the Ministry of Health has been to build a 
healthcare model based on primary care, emphasizing 
population health, and focusing on health promotion and 
prevention, following the guidelines for Sustainable 
Development Goals of the World Health Organization 
(WHO).10,11 
In Chile, public primary care is mostly overseen by each 
Municipality (346 local governments) with 10% being 
managed directly by the local health care service 
administrator. These primary care centers are divided by 
size as small (rural health posts, 4,000 average population), 
medium (community health centers, 8,000 average 
population) and large (family health centers, 20,000 
average population).12 These centers are organized using 
the family medicine model, proposed by WHO, with a 
multi-professional practice that encompasses not only the 
patient, but the family and the community.13 Centers are 
composed of one or several multidisciplinary teams 
(depending on size of the center) that provide healthcare 
for a geographically defined population. Family health 
centers [Centro de Salud Familiar] (CESFAM) are the larger 
providers of local primary care and also coordinate the 
smaller centers in their territories. Healthcare teams are 
composed by health professionals, including physicians, 
registered nurses, dietitians, psychologists, dentists, 
physiotherapists, and midwives. Other professionals such 
as social workers, speech therapists and pharmacists are 
not part of the core teams but are present in some 
centers.14  
Interventions performed by these healthcare teams must 
encompass promotion, prevention, recovery, and 
rehabilitation actions over the lifespan of the individual. To 
carry out these actions, primary care has dual funding 
system, with a per capita system as well as a pay-for-
performance scheme.14 The per capita system is the main 
source of funding, and covers most health services, 
medications and personnel for each center based on the 
assigned geographic population. In the pay-for-
performance scheme or primary care reinforcement 
program, specific interventions such as respiratory health 
care, dental care and dispensing of chronic medications 
receive additional funding depending on some health 
outcomes and the number of patients’ visits and health 
checks. Additional remuneration is provided when 
predefined goals are achieved.14 Both schemes are 
determined by the Ministry of Health, while the latter 
scheme is used as a leverage to encourage primary care 
providers to engage with public health objectives, including 
effective collaboration with other levels of care.15   
 
MEDICATION ACCESS IN PRIMARY HEALTH 
CARE 
In 2019 Chile had the highest price for original branded 
medicines in the Latin American region, with USD 14.1 per 
unit. In contrast, generics prices were one of the lowest 
with USD 1.30 per unit. Generics represented only 48% of 
total sold units for prescription medicines.16 As a 
consequence, medications are more than 50% of out-of-
pocket payments in Chile, influencing the use of chronic 
medicines.3 
Patients from ISAPREs must purchase their medicines from 
privately owned community pharmacies. For some chronic 
conditions, following the GES policy, ISAPREs cover part or 
all the out-of-pocket payments of some medications (15 to 
35% for original medications and >80% for generics). This 
occurs only if the patients attends an approved healthcare 
provider and has the prescriptions dispensed in certain 
specifically contracted community pharmacies (mostly 
chain companies).7 Patients can pay for additional 
medication coverage (up to 80%) on their ISAPREs or from 
another insurance company, but this does not include all 
medicines, and patients are still required to attend certain 
contracted pharmacies. There is also an annual cap.5 
Patients that belong to FONASA receive their medications 
free of charge in state owned pharmacies embedded in 
each public health center. These pharmacies have limited 
availability of chronic and acute medications depending on 
the level of healthcare provided in the establishment. 
Physicians are encouraged to prescribe these specific 
medications.6  
To reduce out-of-pocket payments and improve medication 
accessibility, publicly owned pharmacies have programs 
that guarantee most chronic medications for FONASA 
users: The Ministry program and the Pharmacy Funds 
program [Fondo de Farmacia] (FOFAR) and both provide 
additional funding to avoid supply issues.6 In the Ministry 
program, the primary care division of the ministry of health 
buys and distribute to each health service coordinator or 
municipality all medications covered by FONASA for 
epilepsy, chronic obstructive pulmonary disease (COPD), 
asthma, osteoarthritis, depression, Parkinson’s disease, 
hypothyroidism, insulin for type-2 diabetes mellitus, and 
contraception. FOFAR includes additional funding for the 
treatment of hypertension, type-2 diabetes and 
dyslipidemias.19 However, it is not uncommon that patients 
must buy a proportion of their medicines in community 
pharmacies, as public pharmacies usually have shortages 
on medicines not included by these programs and/or have 
outdated medications.20 In 2019 FONASA implemented a 
coverage program for these patients (12% to 30% of 
discounts) in a small number of selected community 
pharmacies, but it has low implementation and only in a 
reduced list of medicines.21  
To reduce out-of-pocket payments in medications, a non-
profit model of pharmacies, called municipal or solidary 
pharmacies, were created by some municipalities in 2015, 
providing medications at almost cost-prices to their 
population. In 2020 there are more than 160 municipal 
pharmacies, with their prices being at least 50% lower than 
privately owned community pharmacies.21  
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COMMUNITY PHARMACIES AND 
PHARMACEUTICAL SERVICES 
In 2019 there were 3,818 community pharmacies, including 
municipal pharmacies, in Chile, with almost half of them 
belonging to three chain pharmacy companies. These chain 
pharmacies represent more than 90% of the national 
market and are mostly located in urban areas, as there are 
no geographic restrictions for opening pharmacies in Chile. 
The rest of community pharmacies are mostly small or 
medium businesses that are evenly distributed over the 
country. Interestingly there are 54 small municipalities in 
Chile that do not have a community pharmacy on their 
territories, and municipal pharmacies have been proposed 
as a solution to this lack of medication access.21 
There is no obligation for pharmacy owners to be 
pharmacists, however, since 1984 the employment of 
pharmacists during operating hours is mandatory, and they 
must be available for patient counselling, prescription 
supervising and dispensing of certain medications. Since 
2015, the legislation identified community pharmacies as 
healthcare centers, guaranteeing the rational use of 
medicines and providing pharmacovigilance services.22 
However, the role of these community pharmacists is 
mostly in management, with little to no direct contact with 
patients and with pharmacy technicians performing most of 
medication dispensing. Community pharmacists are often 
described as ‘behind-the-counter professionals’ with a 
minor health role, especially in chain pharmacies. On the 
other hand, smaller pharmacies usually provide some 
patient counselling, but their market share is low and as 
these services are not funded, so it is not prioritized.23 
Community pharmacies, especially those owned by the 
chain companies, have a negative public perception.24 In 
1995 and 2008 the three main chain pharmacies were 
found guilty of collusion due to price-fixing of several 
products.25-26 The companies were penalized with a fine of 
USD 60 million as compensation.25-26 As prices of 
medications continue to increase, Chilean consumers are 
reported to have one of the worst opinion of pharmacies 
and the pharmaceutical industry in the Latin American 
region.24 
Interestingly, one of the chain pharmacies between 2003 
and 2005 developed a pharmaceutical care program, with 
pharmacists providing medication reviews to chronic 
patients. The service was free of charge, and patients 
signed up voluntarily at their local chain pharmacy. A 
randomized-controlled trial of 6 months duration was 
conducted in 2003 to evaluate the program, finding a 
statistically significant reduction on lipid levels.16 
Nevertheless, the program was discontinued in 2005. 
There is a perception that most small privately owned and 
publicly owned municipal pharmacies provide patient 
counselling and other services, however, there has been no 
evaluation and these services are also not standardized.  
 
PRIMARY HEALTH CARE SYSTEM AND 
PHARMACEUTICAL SERVICES 
The presence of pharmacists in the primary care network 
has been historically low. Prior to 2014 (and FOFAR), a 
small team of pharmacists from each of the 29 autonomous 
health services coordinators remotely supervised the public 
primary care pharmacies in their territories. As there was 
no legal obligation to employ pharmacists, less than 10% of 
the primary care centers had a full-time pharmacist. Since 
2014, FOFAR has included funds to employ pharmacist in 
the larger primary care centers, reaching more than 100 by 
2016.14 These pharmacists were used mostly for 
management functions, but some of them have started to 
provide clinical services at their own initiative or by 
requests from local clinical teams. 
Because of the increasing number of pharmacists and 
growing interest from health centers and the Ministry of 
Health, a 6-months randomized controlled trial was 
conducted in 2016 in the largest primary care center in 
Chile to explore the impact of medication reviews with 
follow-up on 212 cardiovascular older patients. The study 
provided initial evidence that pharmacists could 
significantly improve the control of hypertension, type-2 
diabetes and dyslipidemias in the Chilean primary care 
setting.27 The Ministry of Health, responding to these 
results, added pharmacists to the 2017 national 
cardiovascular care program guidelines, stating that where 
available, pharmacists should participate in clinical teams 
providing services for cardiovascular patients. These 
guidelines were the first in Chile to include pharmacists in 
primary health care teams.28 
Following this study, a cluster randomized controlled study, 
the Polaris trial, was conducted between 2018 and 2019 to 
provide further evidence on clinical and economic 
outcomes of the inclusion of pharmacists in primary care 
teams. The results provided evidence that the intervention, 
a comprehensive medication review with follow up, was a 
cost-effective addition to control cardiovascular risk 
factors. After the Polaris trial, and as more clinical 
guidelines included pharmacists in 2018 and 2019, the 
Ministry has been increasing the number of full-time 
pharmacists in primary care centers, reaching more than 
450 or >80% of the largest centers in 2020.14  
Prior to 2018, there were only two pharmaceutical services 
defined in the official national registry determined by the 
Ministry: pharmacovigilance services and pharmaceutical 
care. As the provision of pharmaceutical services grew, this 
registry was not sufficient to describe all of pharmacists’ 
actions taking into account that primary care pharmacists 
have access to all clinical information of their patients. In 
2019, major modifications were made. An official list of 
pharmaceutical services, with some of them using the 
Pharmaceutical Care Network Europe (PCNE) classification 
for medication reviews, was published (see Table 1).29 
Despite the inclusion of these services on the list of official 
clinical activities for the primary care network, most 
pharmacists are unable to provide them, as they are 
predominantly focused on management tasks. This was 
observed and reported in the Polaris trial and has been 
reported by the international literature as one of the main 
barriers for the implementation of pharmaceutical 
services.30  
In 2020 the Ministry of Health implemented a 
multimorbidity care model in some primary care centers. 
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This is a health stratification model. It uses the number of 
chronic conditions (from an official list of more than 50 
diseases) and socioeconomic and psychosocial factors, 
which are then used as risk scores. Some health conditions 
such as cardiovascular diseases, severe kidney disease and 
dementia are defined as ‘critical’ and provide double 
scoring. Patients are then classified as healthy or having a 
null risk (score 0), low risk (score 1), intermediate risk 
(score 2 to 4) and high risk (score ≥5), and health services 
are provided depending on each patient classification. The 
Ministry is employing more professionals, including part-
time pharmacists, to support the implementation of 
multimorbidity care, and it is planned that all the primary 
care networks will use this model by 2030. Pharmacists are 
expected to provide pharmaceutical services to the higher-
risk patients, but the nature and details of these services 
have not been defined.31 
In contrast, the private primary care network does not 
provide pharmaceutical services, as they are not funded by 
ISAPREs. FONASA is commonly used as reference by private 
companies for service coverage, but pharmaceutical 
services have not received a specific codification or pricing.7  
 
PHARMACIST TRAINING AND PROFESSIONAL 
REPRESENTATION 
In Chile, to be a pharmacist one must complete a 10-to-11 
semester academic program. There are currently 17 
pharmacy schools. The academic level of a pharmacy 
degree is at a level between a bachelor and a master’s 
degree if compared to international standards 
(‘professional’ level in Chile). More than 50% of these 
programs consist of basic science training such as chemistry 
and biology. Health-related subjects are scarce and 
represent less than 10% of the programs. Furthermore, 
most pharmacy schools do not provide training on 
interviewing skills, and pharmacists usually lack the abilities 
and experience needed to provide patient counselling.23  
As a response to a need for pharmacists with clinical skills 
in the hospital healthcare system, the Ministry of Health 
approved a specialist clinical pharmacist program in 2018, 
recognizing that additional training was required for this 
level of care.32 It is a two-year program and is being 
provided only by two pharmacy schools in 2020, with a 
quota of less than 10 graduates every year. From 2021, the 
ministry will require a 3-year program. In 2020, there are 
still less than 100 clinical pharmacy specialists in Chile. 
Nevertheless, the employment of these specialists is 
funded only for hospital care. Some universities have 
Table 1. Official pharmaceutical services for the public primary health care network. 
Pharmaceutical service Description Patient-per-hour rates 
Clinical services 
Medication review without visit 
(type 2b or intermediate by 
PCNE) 
Pharmacists conduct medication reviews using all information available in 
official medical records and pharmacological prescriptions. Pharmacists 
would add their findings and suggestions to the medical records to be 
considered by physicians. 
4 – 6 PPH 
Medication review with visit 
(type 3 or advanced by PCNE) 
A one-or-twice yearly visit added to the previous service to detect 
nonadherence motives and include additional patient’s information. 
3 – 4 PPH 
Medication review with follow-
up (type 3 or advanced by 
PCNE) 
A systematic, structured service using the Polaris method as guideline. The 
service consists in at least three visits with the patient (initial, intervention 
and follow-up). The pharmacist meets with the physician after the initial visit 
to discuss the findings and suggest pharmacotherapy modifications if 
needed. Any agreed intervention would be directly implemented and 
registered by the pharmacist in the next visit, depending on the patient's 
acceptance. The pharmacist would monitor the results of the interventions 
in follow-ups and perform the service until every health problem is resolved, 
if the patient does not want to continue or if the pharmacist discharges the 
patient. 
2 PPH for initial visit 
3 PPH for follow-ups 
Individual education Pharmacists implement educational programs to increase patient’s 
knowledge and health literacy. This program would be comprehensive, 
adapting to the patient’s needs and in agreed topics. 
3 – 4 PPH 
Pharmacovigilance Detection, report and solving of adverse drug reactions. 4 – 6 PPH 
Medication reconciliation A simplified review of the medications conducted when a patient changes 
their level or site of care (e.g. hospital to primary care or private to public 
system) to prevent therapeutic duplicities and omissions. 
6 – 12 PPH 
Group education A group session where the pharmacist carries out a flexible activity 
according to the group of patients’ needs and the educational objective. 
Pharmacists can implement group education in subjects such as the use of 
medicines, medication adherence, medicinal herbs, and others. The 
pharmacist can also contribute to group educations organized by other 
professionals. 
2 PPH 
Home visit Pharmacists provide pharmaceutical services at the patient’s home. This 
service is reserved for dependent patients and their caregivers. 
1 PPH 
Non-clinical services 
Medication quality control Pharmacists must report to the health authorities when medication quality 
issues are detected in the health center, sending samples to be analyzed. 
-- 
Adverse drug events Pharmacists must report and resolve adverse drug events that occur in the 
health center. 
-- 
PCNE: Pharmaceutical Care Network Europe; PPH: patient-per-hour. 
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developed additional postgraduate courses for ambulatory 
pharmacists, and these are increasingly being funded by 
public entities to incentivize the provision of 
pharmaceutical services in primary care centers.  
After graduating, pharmacist can pay a monthly fee to join 
the Chilean Pharmacists Association [Colegio de Químicos 
Farmacéuticos y Bioquímicos de Chile]. The role of this 
organisation is primarily political advocacy and does not 
receive funding from the government. About 10% of 
pharmacists in Chile belong to the Association. The 
Pharmacists Association represents pharmacists on 
government committees and is usually invited to 
participate as a stakeholder. However, as most pharmacists 
are not part of the Pharmacists Association, it has a limited 
influence. There are a number of smaller independent 
organizations focused on segments such as the 
pharmaceutical industry, community pharmacies and some 
scientific associations for primary or hospital care 
pharmacists. They often play a similar role to the 
Association. 
 
OPPORTUNITIES FOR PHARMACEUTICAL 
SERVICES IN CHILE 
Chilean pharmacy program and the Pharmacists 
Association 
The pharmacy programs should be modified to reinforce 
clinical skills from the initial undergraduate years, as these 
competencies must be developed over time. We 
understand that pharmacists can work in very different 
areas and they require a wide scope of skills, but Chilean 
healthcare system is requiring more clinical involvement. 
The international literature supports the provision of 
pharmaceutical care.33 Training should provide direct 
contact with patients at different levels (hospital and 
ambulatory care), and pharmacists should be able to 
provide clinical services such as basic or intermediate 
medication reviews, pharmacovigilance services and 
patient counselling without additional postgraduate 
courses. 
As for the Pharmacists Association, its role should be 
expanded to provide more than political advocacy and 
representation of the pharmaceutical profession. The 
Pharmacists Association should influence pharmacy 
undergraduate and postgraduate programs, establishing 
and certifying professional standards for all pharmacy 
segments, as well as participating in developing policies 
related to medicines. The Pharmacists Association should 
also negotiate medication coverage, provision of 
pharmaceutical services and pharmacists’ involvement in 
the health care system. It could provide guidance to the 
government and generate evidence related to the 
efficiency and effectiveness of pharmaceutical services, as 
is the case in other countries such as Australia, Canada, and 
Spain. To accompany and support this expanded role, 
Association membership should be mandatory for all 
pharmacists.  
Opportunities to further develop pharmaceutical services 
in primary health care 
Most recent primary health care policies in Chile recognize 
the role of primary care pharmacists, employing 
pharmacists and in most instances including them in in care 
teams. Therefore, it is necessary that all large primary care 
centers have a full-time pharmacist (or more than one if 
the center is large enough). With the implementation of 
the multimorbidity care model, pharmacist would be able 
to provide specific services depending on patients’ needs. 
Within this model we propose a risk-based approach using 
the official classification and the number of medications, 
where higher-risk patients receive more complex and time-
consuming pharmaceutical services. The proposed 
structure is described on Figure 1.31 Pharmaceutical 
services such as medication reconciliation, 
pharmacovigilance, individual education, home visits, and 
non-clinical services are not included in the proposal as we 
believe that they do not depend on this classification and 
should be provided when necessary. 
Medication review with follow-up has been shown to 
improve the control of some chronic conditions, as 
Figure 1. Proposed structure for pharmaceutical services on the multimorbidity care model. 
G0: null or unknown risk; G1: low risk; G2: intermediate risk; G3: high risk. 
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demonstrated in the Polaris trial, but its implementation 
may be constrained as it requires physicians’ time. Allowing 
pharmacists to initiate or modify existing pharmacological 
treatments for chronic conditions could improve the 
efficiency of the health system. This has been successfully 
tested in similar settings such as the UK’s General Practice 
Pharmacists program.34 Primary care pharmacists could 
receive additional 3 to 6 months certified training by 
academic institutions on prescribing of medicines and other 
clinical skills. Furthermore, the role of specialist 
pharmacists, currently restricted to hospitals, could be 
expanded to primary care, where they could enhance 
quality of care and provide more complex services. 
The implementation of pharmaceutical services in private 
primary care will not be possible until coverage and 
remuneration is provided by ISAPREs. It is imperative that 
FONASA specifies reference pricing for pharmaceutical 
services to encourage the private sector. They could use 
the costs of services provided by other health professionals 
such as general practitioners or physiotherapists, the list of 




As the provision of pharmaceutical services in community 
pharmacies in Chile is almost non-existent, there are many 
potential opportunities. Municipal pharmacies, being non-
profit establishments, have a great opportunity to provide 
services, but there is a need for an extensive 
implementation program. Municipal pharmacies have 
several differences with primary care pharmacies as most 
of them lack private attention zones and access to the 
patient's medical records, and there is no structured 
communication method with primary care physicians or 
pharmacists.  
For other community pharmacies, if pharmaceutical 
services are not covered by insurance, it is unlikely that 
they will be implemented. The literature has described 
some models of funding, where patients or the government 
pay for these services based on their impact on health 
outcomes.35 However, apart from small pharmacies, we 
believe that these programs would not be successful until 
patients' perception of pharmacies is improved, and 
pharmacists can provide pharmaceutical services as part of 
their main tasks. Furthermore, these services should not 
duplicate those provided at primary care centers to avoid 
repeating tasks and professional conflicts. Community 
pharmacies could integrate new services such as tobacco 
cessation programs, pharmaceutical immunization, and 
minor ailments prescription, all described by the literature 
as effective.36-38 
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